El año pasado, Ridgetech Inc generó 65.21M USD en su segmento con mejor rendimiento, Prescription drugs. China (Mainland) realizó la mayor aportación, representando 132.16M USD el año pasado.

Por negocio

Ingresos operativos

Proporción

Anual

Anual

Trimestral

Prescription drugs

OTC drugs

Nutritional supplements

Medical devices

TCM

Sundry products

FY2024

FY2023

FY2022

FY2021

FY2020

Prescription drugs

65.21M(42.19%)

59.44M(39.94%)

79.95M(48.63%)

62.88M(47.23%)

52.35M(44.62%)

OTC drugs

55.84M(36.13%)

56.52M(37.98%)

55.04M(33.48%)

44.33M(33.29%)

41.45M(35.33%)

Nutritional supplements

14.92M(9.65%)

11.79M(7.92%)

12.10M(7.36%)

7.97M(5.99%)

6.96M(5.93%)

Medical devices

10.95M(7.08%)

8.18M(5.50%)

7.48M(4.55%)

9.50M(7.14%)

7.22M(6.15%)

TCM

4.37M(2.83%)

10.61M(7.13%)

5.91M(3.60%)

5.08M(3.81%)

5.91M(5.03%)

Sundry products

3.27M(2.12%)

2.28M(1.53%)

3.91M(2.38%)

3.38M(2.54%)

3.44M(2.93%)

Por región

Ingresos operativos

Proporción

Anual

Anual

Trimestral

China (Mainland)

FY2026

FY2025

FY2024

FY2023

FY2022

China (Mainland)

132.16M(100.00%)

119.97M(100.00%)

154.54M(100.00%)

148.81M(100.00%)

164.39M(100.00%)